Danziten, a new formulation of nilotinib, may improve treatment adherence in patients with Philadelphia chromosome-positive ...

Azurity Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved Danziten™, the first and only nilotinib with no mealtime restrictions indicated for adult patients ...

For chronic myeloid leukemia (CML) patients, there is a promising new first-line drug approval with asciminib (brand name ...

Neurogene has a $903M market cap with two phase 1/2 assets, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease.

Transcription activation of genes by estrogens is driven by enhancers, which are often located within the same Topologically Associating Domain (TAD) as non-targeted promoters. We investigated how ...

Researchers sought to determine whether combination decitabine, venetoclax, and ponatinib would be effective in patients with accelerated phase CML.

If approved, donidalorsen would be a first-in-class RNA-targeted medicine for hereditary angioedema. The agency’s goal date ...

In conclusion, this intriguing report builds on the work of many other groups by further unraveling MECP2 function in the ...

The FDA approved zolbetuximab (Vyloy) on October 18, 2024, as a first-line treatment for locally advanced unresectable or ...

Are you ready to learn more about Marvel Phase 6? If you opened this article, you should be. At the time of this guide's last update, we're still around nine months away from the third and final ...

Welcome to TechRadar's Marvel Phase 5 hub. In this article, you'll find the latest news and rumors on Marvel Cinematic Universe (MCU)'s current phase, which is due to end in July 2025. It's ...